Atovaquone-Proguanil versus Chloroquine-Proguanil for Malaria Prophylaxis in Nonimmune Pediatric Travelers: Results of an International, Randomized, Open-Label Study
Open Access
- 15 June 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (12), 1716-1723
- https://doi.org/10.1086/421086
Abstract
Atovaquone-proguanil has been shown to be effective and well tolerated for malaria prophylaxis in residents of countries of endemicity and in nonimmune adult travelers, but data about traveling children are limited. In a randomized, open-label, multicenter prophylaxis trial, 221 nonimmune pediatric travelers (age, 2–17 years) received either atovaquone-proguanil or chloroquine-proguanil. Safety and clinical outcome were evaluated 7, 28, and 60 days after travel. By posttravel day 7, a total of 39 (35%) of 110 atovaquone-proguanil and 41 (37%) of 111 chloroquine-proguanil recipients reported ⩾1 adverse event. The data indicate that, over the course of treatment, fewer atovaquone-proguanil recipients had treatment-related adverse events (8% vs. 14%), including gastrointestinal complaints (5% vs. 10%). Two subjects discontinued prophylaxis because of drug-related adverse events; both had received chloroquine-proguanil. Observed compliance with prophylaxis was similar before and during travel, but it was higher for atovaquone-proguanil in the posttravel period. No study participant developed malaria. Atovaquone-proguanil was well tolerated and is an important addition to the limited arsenal of prophylactic agents available to children.Keywords
This publication has 19 references indexed in Scilit:
- Traveling with Infants and Young Children Part I: Anticipatory Guidance: Travel Preparation and Preventive Health AdviceJournal of Travel Medicine, 2006
- Efficacy of Atovaquone/Proguanil for Malaria Prophylaxis in Children and Its Effect on the Immunogenicity of Live Oral Typhoid and Cholera VaccinesClinical Infectious Diseases, 2002
- Randomized, Placebo‐Controlled Trial of Atovaquone/Proguanil for the Prevention ofPlasmodium falciparumorPlasmodium vivaxMalaria among Migrants to Papua, IndonesiaClinical Infectious Diseases, 2002
- Atovaquone‐Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers: Results from a Randomized, Double‐Blind StudyClinical Infectious Diseases, 2001
- Malaria Chemoprophylaxis in the Age of Drug Resistance. I. Currently Recommended Drug RegimensClinical Infectious Diseases, 2001
- Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind studyThe Lancet, 2000
- Health Advice and Immunizations for TravelersNew England Journal of Medicine, 2000
- Seroconversion to Circumsporozoite Antigen of Plasmodium falciparum Demonstrates a High Risk of Malaria Transmission in Travelers to East AfricaClinical Infectious Diseases, 1999
- Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in childrenThe Lancet, 1998
- Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellersBMJ, 1996